12 May 2026 Louisiana-based 28bio, a neurotechnology company engineering human brains at-scale exhibiting memory, learning, and cognitive functions, has announced the launch of CNS-3D Myelinated Organoids. The ability to measure and understand the myelination process has historically relied on animal models, where myelin loss and repair occur faster and more completely than in humans, creating a translational gap that fails to reflect the slower, often incomplete remyelinat

29 May 2026 Oegstgeest, the Netherlands-based Mimetas announces it is launching OrganoAccess™ – a complete solution for establishing a robust, perfusable network‑like mesh of very small blood vessels in an organ-on-a-chip. This latest product complements existing Mimetas microphysiological products and CRO services, addressing the growing need for more complex and physiologically relevant 3D tissue models, particularly those that incorporate functional vasculature and en

16 April 2026 Sydney, Australia-based Inventia Life Science announces the launch of RASTRUM™ Validated Solutions, a new product offering designed to help drug discovery teams generate decision-grade data from human-relevant 3D cell models with greater speed, confidence, and reproducibility. Through its RASTRUM bioprinting platform, workflow-driven software, and scientific expertise, Inventia Life Science supports researchers with biologically relevant in vitro models at s

14 April 2026 Zurich, Switzerland-based CRO InSphero, the global leader in 3D cell-based assays and organ-on-chip systems, announces the commercial launch of the 3D InSight™ Drug-Induced Gastrointestinal Toxicity (DIGIT) platform, a standardized, high-throughput screening solution for early assessment of gastrointestinal (GI) liabilities in drug discovery. Despite efforts to flag GI toxicity risk early in the drug discovery process, DIGIT remains among the most common cau

20 May 2026 Zurich-based CRO InSphero, global leader in advanced 3D in vitro products and services, announces the acquisition of PhenoVista Biosciences to expand its high-content imaging and phenotypic analysis capabilities for drug discovery and safety testing. San Diego-based CRO PhenoVista Biosciences, Inc., is a leading provider in high-content imaging, cell painting, and functional cellular analysis for the biopharmaceutical industry. Their diverse repertoire includ

18 February 2026 Edinburgh-based CRO Axol Bioscience, leading provider of induced pluripotent stem cell (iPSC) technologies for drug discovery and research, announces that it has acquired the ophthalmology business of the Newcastle-based CRO Newcells Biotech. The acquisition of Newcells’ ophthalmology business includes its specialist team, facilities and intellectual property related to supply of proprietary iPSC-derived products and ophthalmology research services. Devel

18 Mars 2026 The purpose of FDA's draft guidance is to provide drug developers with a validation framework of alternatives to animal testing for nonclinical safety, here referred to as new approach methologies (NAM), such as in vitro and in silico methods. The document emphasises that a NAM does not need to be formally validated before FDA’s drug review centres (primarily the Center for Drug Evaluation and Research) can evaluate it as part of a drug development programme. In

© Sania Ristic 2026 — Licensed under CC BY‑NC‑ND 4.0 01 June 2026 In response to the 2023 European citizens’ initiative (ECI) ‘Save Cruelty-Free Cosmetics – Commit to a Europe Without Animal Testing,’ the European Commission (EC) has published its 'Roadmap towards phasing out animal testing for chemical safety assessments'. This response arrives against the backdrop of more than 15 million animals being used in animal experiments between 2015-2023 by companies to prove that

25 Mars 2026 The UK's Medicines and Healthcare products Regulatory Agency (MHRA), responsible for ensuring that medicines and healthcare products available in the UK are safe and effective, has announced new regulatory guidance in support of the government policy to phase out animal testing. This guidance applies to the MHRA’s approach to its review of Clinical Trial Authorisation applications and of Marketing Authorisation applications for medicinal products. The MHRA star

08 January 2026 While the human central nervous system (CNS) has often been modelled with organoids, progress in constructing the peripheral nervous system (PNS) has been relatively limited. Yet, the PNS plays a crucial role in communication between different areas of the body and the brain and dysfunction in PNS has been tied to a number of chronic diseases. The PNS has two main subsystems, one of which is the autonomic nervous system, which automatically controls physio

27 January 2026 Despite important investment in biomedical research, the most common malignant adult brain tumor - glioblastoma (GBM) - remains largely refractory to existing treatments. Tumors can evade or suppress immunity through a variety of mechanisms, including antigen heterogeneity and immunosuppressive signaling. Owing in large part to inter-species differences in the immune system and the tumor microenvironment (extracellular matrix composition, stromal cells beha

10 February 2026 European pioneers of human-based microphysiological systems (MPS) announce the launch of of IAMPS – the Industry Alliance for Microphysiological Systems, dedicated to advancing MPS technologies. This alliance was formed by leading innovators in next gen human biology platforms – AlveoliX (Switzerland), BiomimX (Italy), chiron (Netherlands), Dynamic42 (Germany), InSphero (Switzerland), MIMETAS (Netherlands), NETRI (France), React4Life (Italy), and TissUse (